Circulating LncRNAs landscape as potential biomarkers in breast cancer

Abstract

The delay in diagnosis and treatment of breast cancer results in low survival rates and high mortality. Thus, it is essential to characterize new therapeutic targets and prognostic breast cancer biomarkers. The rising evidence suggested that long non-coding RNAs (lncRNAs) expression levels are deregulated in human cancers and can use as biomarkers for the rapid diagnosis of breast cancer. In the present study, a Quantitative Real-time polymerase chain reaction (qRT-PCR) technique was used to measure twenty oncogenic and tumor suppressor lncRNAs expression levels in whole blood samples of breast cancer patients and normal controls. Blood samples from 30 healthy women and 30 female breast cancer patients were collected. Then cDNA was synthesized from the extracted RNA blood. The expression level of lncRNAs measured and analyzed by LinReg PCR and REST software and the correla tion between lncRNAs dysregulation and clinical characteristics and prognosis were also analyzed by SPSS software. The comparison between the expression levels of lncRNAs in the blood samples of breast cancer patients compared with healthy individuals revealed that some lncRNAs (MEG3, NBAT1, NKILA, GAS5, EPB41L4A-AS2, ZFAS1, MVIH, Z38, and BC040587) were down regulated. In contrast, other lncRNAs (H19, SPRY4-IT1, UCA1, AC026904.1, CCAT1) were up-regulated, signi cantly. It was shown that the expression levels of NKILA, NBAT1, and ZFAS1 lncRNAs were related to tumor size, and BC040587expression level related to age, node metastasis, tumor size, and grade (P<0.05). The association between H19 and SPRY4-IT1 lncRNAs with HER-2 was con rmed statistically (P<0.05). Our data highlighted the correlation of BC040587, H19, and SPRY4-IT1 lncRNAs with clinicopathological traits in breast cancer patients suggesting their future applications as novel biomarkers and therapeutic targets in breast cancer. In conclusion, circulating lncRNAs could consider as the prognostic and predictive markers in breast cancer.

The Role of Urothelial Cancer-Associated 1 in Gynecological Cancers

“…Furthermore, UCA1 concentrations were measured to be even more elevated in the blood samples of patients in advanced stages, and women with lymph node and distant organ metastatic disease [ 4 , 5 ]. Nonetheless, one study found that UCA1 levels were not significantly correlated with clinicopathological characteristics, whereas another study proposed that UCA1 expression was reduced in left-sided MBC tumors, suggesting a potential correlation between UCA1 levels and laterality in MBC patients [ 2 , 30 ]. Almost all studies identified overexpressed UCA1 levels in BC tissues compared to the healthy ones, while additionally revealing the remarkable association of high UCA1 levels with short overall survival and advanced clinical stage disease [ 31 , 32 , 34 , 35 , 37 , 38 , 40 , 41 ].…”

“…After evaluating the expression of multiple lncRNAs in blood samples of untreated BC patients, Pourramezan et al identified that UCA1 was significantly upregulated in BC patients compared to healthy women; however, the correlation between UCA1 levels and clinicopathological characteristics, such as race, histological grade, tumor size, TNM staging, and molecular subtypes, was not statistically significant [ 30 ].…”

The mechanism and therapeutic potential of lncRNA MIR497HG/miR-16-5p axis in breast cancer

“…Meanwhile, ROC curve reflected the possible diagnostic significance of MIR497HG. Through literature review, lncRNA BC040587 was verified to be low expressed in breast cancer, and related to some clinical indicators of patients (age, grade, metastasis), with the potential of diagnostic and prognostic indicators of breast cancer [ 21 ]. LncRNA NEAT1 levels decreased, and the ability of NEAT1 to differentiate breast cancer patients was confirmed by multivariate analysis and ROC method [ 22 ].…”

Breast Cancer Chemoresistance: Insights into the Regulatory Role of lncRNA

“…LncRNA H19 is also at the stage of clinical trials for glioblastoma, ovarian, bladder, and pancreatic cancer [267]. For breast cancer, a recent work of Pourramezan et al [268] established a list of fifteen circulating lncRNAs that are differentially expressed in BC patients compared to healthy women. They evidenced that the downregulation of the lncRNA NKILA and NBAT1 are linked to tumor size, whereas the blood concentration of H19 and SPRY4-IT1 is a good parameter to discriminate between BC patients and controls.…”